Hydroxychloroquine in lupus pregnancy.

OBJECTIVE Hydroxychloroquine (HCQ) is often needed to manage disease activity in systemic lupus erythematosus (SLE) during pregnancy. The purpose of this study was to examine lupus activity and pregnancy outcomes in women with SLE treated or not treated with HCQ during pregnancy. METHODS This was a prospective study of pregnancies in women with SLE who were evaluated between 1987 and 2002. The pregnancies were divided into 3 groups: no HCQ exposure during pregnancy (163 pregnancies), continuous use of HCQ during pregnancy (56 pregnancies), or cessation of HCQ treatment either in the 3 months prior to or during the first trimester of pregnancy (38 pregnancies). The pregnancy outcomes, fetal outcomes, and lupus activity during pregnancy were compared among these groups. RESULTS The rates of miscarriage, stillbirth, pregnancy loss, and congenital abnormality were not statistically different among the 3 groups. The degree of lupus activity during pregnancy, however, was significantly higher in women who stopped taking HCQ. These women had a higher degree of lupus activity, as measured by the physician's estimate of lupus activity and the SLE Disease Activity Index, as well as an increased rate of flare, during pregnancy. More serious lupus complications, such as proteinuria and thrombocytopenia, were not significantly higher in women who stopped taking HCQ. Women who continued taking HCQ were maintained on a lower average dose of prednisone during pregnancy. CONCLUSION We recommend the continuation of HCQ treatment during pregnancy. Our findings are consistent with prior reports of the absence of fetal toxicity. Similar to studies of nonpregnant women, the cessation of HCQ treatment during pregnancy increases the degree of lupus activity.

[1]  G. Hughes,et al.  Hydroxychloroquine and lupus pregnancy: review of a series of 36 cases. , 1996, Annals of the rheumatic diseases.

[2]  M. Petri,et al.  Frequency of lupus flare in pregnancy. The Hopkins Lupus Pregnancy Center experience. , 2010, Arthritis and rheumatism.

[3]  J. Piette,et al.  Safety of hydroxychloroquine in pregnant patients with connective tissue diseases: a study of one hundred thirty-three cases compared with a control group. , 2003, Arthritis and rheumatism.

[4]  G. Koren,et al.  Ocular toxicity and antenatal exposure to chloroquine or hydroxychloroquine for rheumatic diseases , 2001, The Lancet.

[5]  L. Paufique,et al.  [Retinal degeneration in 2 children following preventive antimalarial treatment of the mother during pregnancy]. , 1969, Bulletin des societes d'ophtalmologie de France.

[6]  T. Einarson,et al.  Birth defects after maternal exposure to corticosteroids: prospective cohort study and meta-analysis of epidemiological studies. , 2000, Teratology.

[7]  W. Wilson.  Classification criteria for antiphospholipid syndrome. , 2001, Rheumatic diseases clinics of North America.

[8]  M. Petri.  Hydroxychloroquine: past, present, future , 1998, Lupus.

[9]  D. Gladman,et al.  Lupus and pregnancy studies. , 1993, Arthritis and rheumatism.

[10]  L. Magder,et al.  Early Risk Factors for Pregnancy Loss in Lupus , 2006, Obstetrics and gynecology.

[11]  M. Petri,et al.  Validity and reliability of lupus activity measures in the routine clinic setting. , 1992, The Journal of rheumatology.

[12]  J. Piette,et al.  Safety of hydroxychloroquine in pregnant patients with connective tissue diseases. Review of the literature. , 2005, Autoimmunity reviews.

[13]  K. Kalunian,et al.  Assessing disease activity in SLE patients during pregnancy , 1999, Lupus.

[14]  J. Reveille,et al.  Systemic lupus erythematosus in three ethnic groups: XVI. Association of hydroxychloroquine use with reduced risk of damage accrual. , 2005, Arthritis and rheumatism.

[15]  R. Day,et al.  Bioavailability of hydroxychloroquine tablets in healthy volunteers. , 1989, British journal of clinical pharmacology.

[16]  C. Gordon,et al.  Anti-inflammatory and immunosuppressive drugs and reproduction , 2006, Arthritis research & therapy.

[17]  M. Petri,et al.  Definition, incidence, and clinical description of flare in systemic lupus erythematosus. A prospective cohort study. , 1991, Arthritis and rheumatism.

[18]  A. Parke,et al.  Hydroxychloroquine in pregnant patients with systemic lupus erythematosus. , 1996, The Journal of rheumatology.

[19]  K. Muir,et al.  Pregnancy outcome and family size in systemic lupus erythematosus: a case-control study. , 1999, Rheumatology.

[20]  C. Aranow,et al.  Review of ACR renal criteria in systemic lupus erythematosus , 2004, Lupus.

[21]  J. Himes,et al.  A United States National Reference for Fetal Growth , 1996, Obstetrics and gynecology.

[22]  J. Esdaile,et al.  Survey of antimalarial use in lupus pregnancy and lactation. , 2002, Journal of Rheumatology.

[23]  N. Lindquist,et al.  Accumulation of Chorio-retinotoxic Drugs in the Foetal Eye , 1970, Nature.

[24]  A. Tincani,et al.  Antimalarial agents in pregnancy , 2002, The Lancet.

[25]  L. Magder,et al.  The impact of increased lupus activity on obstetric outcomes. , 2005, Arthritis and rheumatism.

[26]  M. Petri,et al.  Fetal outcome of lupus pregnancy: a retrospective case-control study of the Hopkins Lupus Cohort. , 1993, The Journal of rheumatology.

[27]  D. Sackett,et al.  Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. , 1992, Arthritis and rheumatism.

[28]  B. Tura,et al.  Hydroxychloroquine (HCQ) in lupus pregnancy: double-blind and placebo-controlled study , 2001, Lupus.

[29]  E. Tsakonas,et al.  A Long-Term Study of Hydroxychloroquine Withdrawal on Exacerbations in Systemic Lupus Erythematosus , 1998 .

[30]  I. Wainer,et al.  Enantioselective disposition of hydroxychloroquine after a single oral dose of the racemate to healthy subjects. , 1995, British journal of clinical pharmacology.

[31]  D. Gladman,et al.  Pregnancy Outcome Following First Trimester Exposure to Chloroquine , 1991, American journal of perinatology.

[32]  K Y Liang,et al.  Longitudinal data analysis for discrete and continuous outcomes. , 1986, Biometrics.

[33]  A. Tincani,et al.  Follow-Up of Infants Exposed to Hydroxychloroquine Given to Mothers during Pregnancy and Lactation , 2005, Journal of Perinatology.

[34]  R. Carr,et al.  Recommendations on screening for chloroquine and hydroxychloroquine retinopathy: a report by the American Academy of Ophthalmology. , 2002, Ophthalmology.